Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Acting Chief Medical Officer | August 26, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date August 26, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,065 |
Ending reported balance
After 2026-08-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-26 · Exercise / conversion · Acquired 1,380 · Balance 5,066 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Row 2 · 2026-08-26 · Sale · Disposed 1 · Balance 5,065 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2026-08-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-26 · Exercise / conversion · Acquired 1,380 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F2: On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
F2: On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 27, 2026 23:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionStock Option · Derivative | 1,380 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001437749-26-029121 · rdgdoc.xml · derivative · entry 3 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,380 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. F2 · derivative.exercise_date: On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 23:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon Stock | 1 | $111.26 | $111.26 |
DisclosureSEC source: 0001437749-26-029121 · rdgdoc.xml · nonDerivative · entry 2 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,065 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Read SEC document |
| August 26, 2026 Filed Aug 27, 2026 23:29 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 1,380 | $0.01 | $6.90 |
DisclosureSEC source: 0001437749-26-029121 · rdgdoc.xml · nonDerivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 20:45 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Option · Derivative | 2,000 | $0.00 Strike: $65.30 | $0.00 |
DisclosureSEC source: 0001437749-26-000304 · rdgdoc.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2026 as follows: 1/12th of the 2,000 options vest on January 31, 2026 and each subsequent month-end thereafter. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 23:16 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 2,000 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000098 · rdgdoc.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2034-12-31 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2025 as follows: 1/12th of 2,000 options on January 31, 2025 and each subsequent month-end thereafter. Read SEC document |
| January 01, 2024 Filed Jan 4, 2024 00:33 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001437749-24-000479 · rdgdoc.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2024 as follows: 833 on January 31, 2024 and each subsequent month-end thereafter. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 20:58 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001437749-23-000159 · rdgdoc.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-12-31 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2023 as follows: 833 on January 31, 2023 and each subsequent month-end thereafter. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 18:47 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001654954-22-000123 · section16.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-12-31 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2022 as follows: 833 on January 31, 2022 and each subsequent month-end thereafter. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:28 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock options · Derivative | 10,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001654954-21-000146 · section16.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2021 as follows: 833 on January 31, 2021 and each subsequent month-end thereafter. Read SEC document |
| January 30, 2020 Filed Feb 21, 2020 02:05 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 6,125 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001654954-20-001798 · section16.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,125 Underlying: Common Stock · 6,125 shares Expires 2030-01-30 F1 · derivative.exercise_date: Stock Options vesting commenced on January 1, 2020 as follows: 510 on January 31, 2020 and each subsequent month-end thereafter. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 00:40 UTC | Monopar Therapeutics NONE · Entity 5152 | Exercise / conversionStock options · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-013406 · section16.xml · derivative · entry 4 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 100 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Original stock options to purchase up to 7,000 shares of common stock vested: 1,190 shares on January 15, 2017; 1,120 shares on February 15, 2017; 1,190 shares on March 15, 2017; 1,120 shares on April 15, 2017; 1,190 shares on May 15, 2017; and 1,190 shares on June 15, 2017. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 00:40 UTC | Monopar Therapeutics NONE · Entity 5152 | Exercise / conversionStock options · Derivative | 18,333 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-19-013406 · section16.xml · derivative · entry 3 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,671 Underlying: Common Stock · 18,333 shares Expires 2027-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Original stock options to purchase up to 32,004 shares of common stock vested 12,000 shares upon grant date of January 1, 2018 and 1,667 shares on the first of each month thereafter. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 00:40 UTC | Monopar Therapeutics NONE · Entity 5152 | Exercise / conversionCommon Stock | 100 | $0.00 | $0.10 |
DisclosureSEC source: 0001654954-19-013406 · section16.xml · nonDerivative · entry 2 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 00:40 UTC | Monopar Therapeutics NONE · Entity 5152 | Exercise / conversionCommon Stock | 18,333 | $6.00 | $109,998.00 |
DisclosureSEC source: 0001654954-19-013406 · section16.xml · nonDerivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2018 Filed Jan 26, 2019 01:58 UTC | Monopar Therapeutics NONE · Entity 5152 | GrantStock option · Derivative | 20,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001654954-19-000796 · section16.xml · derivative · entry 1 RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common stock · 20,000 shares Expires 2028-12-30 F1 · derivative.exercise_date: Stock options vest and become exercisable according to the following schedule: 1,667 shares vest on January 31, 2019 and the last day of each subsequent month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.